Aug. 15, 2022 — The Inflation Reduction Act passed last week may represent the best outcome the biopharma industry reasonably could have hoped for at a time when so many in Congress are eager to respond to strong public opinion that prescription prices are too high. The new legislation, which reins in some drug costs […]
Read more
July 27, 2020 – The four Executive Orders signed by President Trump on Friday were designed to address drug pricing concerns, but their combined impact is modest and they are “unlikely to have any immediate effect,” according to Coalition for Healthcare Communication Executive Director Jon Bigelow. However, they do “give the president talking points for […]
Read more